NHS England updates CDF List

NHS England has upded the Cancer Drugs Fund List on its website. We have updated our website to correspond.

NHS England updates CDF List

NHS England has updated the Cancer Drugs Fund List. The latest version (v1.350) was uploaded to the NHS England Website on Friday 21, February 2025.

The following changes have been introduced:

Blinatumomab (BLI5)

Recommended for routine commissioning, receiving CDF interim funding - see entry for more information

Pembrolizumab (PEMB31)

Pembrolizumab monotherapy for adjuvant treatment after complete tumour resection in adult patients with UICC/AJCC 8th edition stage IIA or IIB or IIIA or N2 only IIIB non-small cell lung cancer and whose disease has not progressed on recently completed adjuvant platinum- based chemotherapy where the following criteria have been met

Treatment criterion (#16) updated